A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
Clinical trial NCT02264639 · COMPLETED
Trial details
- NCT number
- NCT02264639
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-23
- Primary completion
- 2018-10-22
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.